PARP inhibitor combo shows early promise for patients with and without BRCA mutations
PARP inhibitor combo shows early promise for patients with and without BRCA mutations
How do we select patients for radium 223?
ecancermedicalscience editor's choice for February 2015
Effectiveness of adjuvant chemotherapy on patients with bladder cancer
ASCO GU 2015 news roundup
Taxane response in prostate cancer may not be influenced by androgen receptor variations
Implications of using adjuvant sorafenib and sunitinib in unfavourable renal carcinoma
Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma
Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma
Docetaxel with androgen deprivation therapy combo in hormone-naïve metastatic prostate cancer
VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma
Impact of statins on survival outcomes in metastatic renal cell carcinoma